Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Duration of protection and humoral immunity induced by an adenovirus-vectored subunit vaccine for foot-and-mouth disease (FMD) in Holstein steers.

Sitt T, Kenney M, Barrera J, Pandya M, Eckstrom K, Warner M, Pacheco JM, LaRocco M, Palarea-Albaladejo J, Brake D, Rieder E, Arzt J, Barlow JW, Golde WT.

Vaccine. 2019 Sep 30;37(42):6221-6231. doi: 10.1016/j.vaccine.2019.08.017. Epub 2019 Sep 5.

2.

Enhanced sensitivity in detection of antiviral antibody responses using biotinylation of foot-and-mouth disease virus (FMDV) capsids.

Kenney M, Waters RA, Rieder E, Pega J, Perez-Filguera M, Golde WT.

J Immunol Methods. 2017 Nov;450:1-9. doi: 10.1016/j.jim.2017.07.001. Epub 2017 Jul 6.

PMID:
28689695
3.

Introduction.

Golde WT, Woodland DL.

Vet Immunol Immunopathol. 2016 Nov 15;181:1. doi: 10.1016/j.vetimm.2016.11.001. No abstract available.

PMID:
27912824
4.

Systemic immune response and virus persistence after foot-and-mouth disease virus infection of naïve cattle and cattle vaccinated with a homologous adenovirus-vectored vaccine.

Eschbaumer M, Stenfeldt C, Rekant SI, Pacheco JM, Hartwig EJ, Smoliga GR, Kenney MA, Golde WT, Rodriguez LL, Arzt J.

BMC Vet Res. 2016 Sep 15;12:205. doi: 10.1186/s12917-016-0838-x.

5.

Expanding specificity of class I restricted CD8+ T cells for viral epitopes following multiple inoculations of swine with a human adenovirus vectored foot-and-mouth disease virus (FMDV) vaccine.

Pedersen LE, Patch JR, Kenney M, Glabman RA, Nielsen M, Jungersen G, Buus S, Golde WT.

Vet Immunol Immunopathol. 2016 Nov 15;181:59-67. doi: 10.1016/j.vetimm.2016.07.012. Epub 2016 Jul 27.

PMID:
27498407
6.

Effect of Foot-and-Mouth Disease Virus Infection on the Frequency, Phenotype and Function of Circulating Dendritic Cells in Cattle.

Sei JJ, Waters RA, Kenney M, Barlow JW, Golde WT.

PLoS One. 2016 Mar 23;11(3):e0152192. doi: 10.1371/journal.pone.0152192. eCollection 2016.

7.

Phenotypic, ultra-structural, and functional characterization of bovine peripheral blood dendritic cell subsets.

Sei JJ, Ochoa AS, Bishop E, Barlow JW, Golde WT.

PLoS One. 2014 Oct 8;9(10):e109273. doi: 10.1371/journal.pone.0109273. eCollection 2014.

8.

Characterization of binding specificities of bovine leucocyte class I molecules: impacts for rational epitope discovery.

Hansen AM, Rasmussen M, Svitek N, Harndahl M, Golde WT, Barlow J, Nene V, Buus S, Nielsen M.

Immunogenetics. 2014 Dec;66(12):705-18. doi: 10.1007/s00251-014-0802-5. Epub 2014 Sep 4.

9.

Infection with foot-and-mouth disease virus (FMDV) induces a natural killer (NK) cell response in cattle that is lacking following vaccination.

Patch JR, Dar PA, Waters R, Toka FN, Barrera J, Schutta C, Kondabattula G, Golde WT.

Comp Immunol Microbiol Infect Dis. 2014 Sep;37(4):249-57. doi: 10.1016/j.cimid.2014.07.004. Epub 2014 Aug 12.

PMID:
25150134
10.

Characterization of cytotoxic T lymphocyte function after foot-and-mouth disease virus infection and vaccination.

Patch JR, Kenney M, Pacheco JM, Grubman MJ, Golde WT.

Viral Immunol. 2013 Aug;26(4):239-49. doi: 10.1089/vim.2013.0011. Epub 2013 Jul 5.

11.

Cell mediated innate responses of cattle and swine are diverse during foot-and-mouth disease virus (FMDV) infection: a unique landscape of innate immunity.

Toka FN, Golde WT.

Immunol Lett. 2013 May;152(2):135-43. doi: 10.1016/j.imlet.2013.05.007. Epub 2013 May 30. Review.

PMID:
23727070
12.

Identification of peptides from foot-and-mouth disease virus structural proteins bound by class I swine leukocyte antigen (SLA) alleles, SLA-1*0401 and SLA-2*0401.

Pedersen LE, Harndahl M, Nielsen M, Patch JR, Jungersen G, Buus S, Golde WT.

Anim Genet. 2013 Jun;44(3):251-8. doi: 10.1111/j.1365-2052.2012.02400.x. Epub 2012 Sep 18.

PMID:
22984928
13.

Designing bovine T cell vaccines via reverse immunology.

Nene V, Svitek N, Toye P, Golde WT, Barlow J, Harndahl M, Buus S, Nielsen M.

Ticks Tick Borne Dis. 2012 Jun;3(3):188-92. doi: 10.1016/j.ttbdis.2011.12.001. Epub 2012 Jan 9. Review.

PMID:
22621863
14.

An alternate delivery system improves vaccine performance against foot-and-mouth disease virus (FMDV).

Pandya M, Pacheco JM, Bishop E, Kenney M, Milward F, Doel T, Golde WT.

Vaccine. 2012 Apr 26;30(20):3106-11. doi: 10.1016/j.vaccine.2012.02.049. Epub 2012 Mar 2.

PMID:
22387223
15.

Porcine major histocompatibility complex (MHC) class I molecules and analysis of their peptide-binding specificities.

Pedersen LE, Harndahl M, Rasmussen M, Lamberth K, Golde WT, Lund O, Nielsen M, Buus S.

Immunogenetics. 2011 Dec;63(12):821-34. doi: 10.1007/s00251-011-0555-3. Epub 2011 Jul 8.

16.

Evidence of activation and suppression during the early immune response to foot-and-mouth disease virus.

Golde WT, de Los Santos T, Robinson L, Grubman MJ, Sevilla N, Summerfield A, Charleston B.

Transbound Emerg Dis. 2011 Aug;58(4):283-90. doi: 10.1111/j.1865-1682.2011.01223.x. Epub 2011 Apr 18. Review.

PMID:
21501424
17.

Rapid and transient activation of γδ T cells to IFN-γ production, NK cell-like killing, and antigen processing during acute virus infection.

Toka FN, Kenney MA, Golde WT.

J Immunol. 2011 Apr 15;186(8):4853-61. doi: 10.4049/jimmunol.1003599. Epub 2011 Mar 7.

18.

Induction of foot-and-mouth disease virus-specific cytotoxic T cell killing by vaccination.

Patch JR, Pedersen LE, Toka FN, Moraes M, Grubman MJ, Nielsen M, Jungersen G, Buus S, Golde WT.

Clin Vaccine Immunol. 2011 Feb;18(2):280-8. doi: 10.1128/CVI.00417-10. Epub 2010 Dec 22.

19.

Letter to the editor. Loss of plasmacytoid dendritic cell function coincides with lymphopenia and viremia during foot-and-mouth disease virus infection.

Nfon CK, Toka FN, Kenney M, Pacheco JM, Golde WT.

Viral Immunol. 2010 Jun;23(3):339. doi: 10.1089/vim.2010.let23.3. No abstract available.

PMID:
20565298
20.

Loss of plasmacytoid dendritic cell function coincides with lymphopenia and viremia during foot-and-mouth disease virus infection.

Nfon CK, Toka FN, Kenney M, Pacheco JM, Golde WT.

Viral Immunol. 2010 Feb;23(1):29-41. doi: 10.1089/vim.2009.0078. Erratum in: Viral Immunol. 2010 Jun;23(3):339.

PMID:
20121400
21.

IgA antibody response of swine to foot-and-mouth disease virus infection and vaccination.

Pacheco JM, Butler JE, Jew J, Ferman GS, Zhu J, Golde WT.

Clin Vaccine Immunol. 2010 Apr;17(4):550-8. doi: 10.1128/CVI.00429-09. Epub 2010 Jan 27.

22.

Mutations in classical swine fever virus NS4B affect virulence in swine.

Fernandez-Sainz I, Gladue DP, Holinka LG, O'Donnell V, Gudmundsdottir I, Prarat MV, Patch JR, Golde WT, Lu Z, Zhu J, Carrillo C, Risatti GR, Borca MV.

J Virol. 2010 Feb;84(3):1536-49. doi: 10.1128/JVI.02050-09. Epub 2009 Nov 18.

23.

Natural killer cell dysfunction during acute infection with foot-and-mouth disease virus.

Toka FN, Nfon C, Dawson H, Golde WT.

Clin Vaccine Immunol. 2009 Dec;16(12):1738-49. doi: 10.1128/CVI.00280-09. Epub 2009 Oct 14.

24.

Innate immune defenses induced by CpG do not promote vaccine-induced protection against foot-and-mouth disease virus in pigs.

Alves MP, Guzylack-Piriou L, Juillard V, Audonnet JC, Doel T, Dawson H, Golde WT, Gerber H, Peduto N, McCullough KC, Summerfield A.

Clin Vaccine Immunol. 2009 Aug;16(8):1151-7. doi: 10.1128/CVI.00018-09. Epub 2009 Jun 24.

25.

Accessory-cell-mediated activation of porcine NK cells by toll-like receptor 7 (TLR7) and TLR8 agonists.

Toka FN, Nfon CK, Dawson H, Golde WT.

Clin Vaccine Immunol. 2009 Jun;16(6):866-78. doi: 10.1128/CVI.00035-09. Epub 2009 Apr 15.

26.

Activation of porcine natural killer cells and lysis of foot-and-mouth disease virus infected cells.

Toka FN, Nfon CK, Dawson H, Estes DM, Golde WT.

J Interferon Cytokine Res. 2009 Mar;29(3):179-92. doi: 10.1089/jir.2008.0058.

PMID:
19196070
27.

Immune evasion during foot-and-mouth disease virus infection of swine.

Golde WT, Nfon CK, Toka FN.

Immunol Rev. 2008 Oct;225:85-95. doi: 10.1111/j.1600-065X.2008.00672.x. Review.

PMID:
18837777
28.

Langerhans cells in porcine skin.

Nfon CK, Dawson H, Toka FN, Golde WT.

Vet Immunol Immunopathol. 2008 Dec 15;126(3-4):236-47. doi: 10.1016/j.vetimm.2008.07.012. Epub 2008 Aug 3.

PMID:
18805593
29.

Interferon-alpha production by swine dendritic cells is inhibited during acute infection with foot-and-mouth disease virus.

Nfon CK, Ferman GS, Toka FN, Gregg DA, Golde WT.

Viral Immunol. 2008 Mar;21(1):68-77. doi: 10.1089/vim.2007.0097.

PMID:
18355124
30.

Vesicular stomatitis New Jersey virus (VSNJV) infects keratinocytes and is restricted to lesion sites and local lymph nodes in the bovine, a natural host.

Scherer CF, O'Donnell V, Golde WT, Gregg D, Estes DM, Rodriguez LL.

Vet Res. 2007 May-Jun;38(3):375-90. Epub 2007 Mar 13.

31.

IL-13 replaces IL-4 in development of monocyte derived dendritic cells (MoDC) of swine.

Bautista EM, Nfon C, Ferman GS, Golde WT.

Vet Immunol Immunopathol. 2007 Jan 15;115(1-2):56-67. Epub 2006 Oct 27.

PMID:
17070934
32.

Immunopotentiation of a foot-and-mouth disease virus subunit vaccine by interferon alpha.

de Avila Botton S, Brum MC, Bautista E, Koster M, Weiblen R, Golde WT, Grubman MJ.

Vaccine. 2006 Apr 24;24(17):3446-56. Epub 2006 Feb 20.

PMID:
16522345
33.

A rapid, simple, and humane method for submandibular bleeding of mice using a lancet.

Golde WT, Gollobin P, Rodriguez LL.

Lab Anim (NY). 2005 Oct;34(9):39-43.

PMID:
16195737
34.

Vaccination against foot-and-mouth disease virus confers complete clinical protection in 7 days and partial protection in 4 days: Use in emergency outbreak response.

Golde WT, Pacheco JM, Duque H, Doel T, Penfold B, Ferman GS, Gregg DR, Rodriguez LL.

Vaccine. 2005 Dec 30;23(50):5775-82. Epub 2005 Aug 8.

PMID:
16153756
36.

Constitutive expression of alpha interferon by skin dendritic cells confers resistance to infection by foot-and-mouth disease virus.

Bautista EM, Ferman GS, Gregg D, Brum MC, Grubman MJ, Golde WT.

J Virol. 2005 Apr;79(8):4838-47.

37.
39.

Induction of lymphopenia and inhibition of T cell function during acute infection of swine with foot and mouth disease virus (FMDV).

Bautista EM, Ferman GS, Golde WT.

Vet Immunol Immunopathol. 2003 Mar 20;92(1-2):61-73.

PMID:
12628764
40.

Borrelia burgdorferi-specific monoclonal antibodies derived from mice primed with Lyme disease spirochete-infected Ixodes scapularis ticks.

Mbow ML, Gilmore RD Jr, Stevenson B, Golde WT, Piesman J, Johnson BJ.

Hybrid Hybridomics. 2002 Jun;21(3):179-82.

PMID:
12165143
41.

Characterization and functional analysis of skin-derived dendritic cells from swine without a requirement for in vitro propagation.

Bautista EM, Gregg D, Golde WT.

Vet Immunol Immunopathol. 2002 Sep 25;88(3-4):131-48.

PMID:
12127412
42.

Infection with multiple strains of Borrelia burgdorferi sensu stricto in patients with Lyme disease.

Seinost G, Golde WT, Berger BW, Dunn JJ, Qiu D, Dunkin DS, Dykhuizen DE, Luft BJ, Dattwyler RJ.

Arch Dermatol. 1999 Nov;135(11):1329-33.

PMID:
10566830
43.

Four clones of Borrelia burgdorferi sensu stricto cause invasive infection in humans.

Seinost G, Dykhuizen DE, Dattwyler RJ, Golde WT, Dunn JJ, Wang IN, Wormser GP, Schriefer ME, Luft BJ.

Infect Immun. 1999 Jul;67(7):3518-24.

44.

Vector competence of Ixodes scapularis and Ixodes ricinus (Acari: Ixodidae) for three genospecies of Borrelia burgdorferi.

Dolan MC, Piesman J, Mbow ML, Maupin GO, Péter O, Brossard M, Golde WT.

J Med Entomol. 1998 Jul;35(4):465-70.

PMID:
9701928
45.

Culture-confirmed reinfection of a person with different strains of Borrelia burgdorferi sensu stricto.

Golde WT, Robinson-Dunn B, Stobierski MG, Dykhuizen D, Wang IN, Carlson V, Stiefel H, Shiflett S, Campbell GL.

J Clin Microbiol. 1998 Apr;36(4):1015-9.

46.

Duration of immunity to reinfection with tick-transmitted Borrelia burgdorferi in naturally infected mice.

Piesman J, Dolan MC, Happ CM, Luft BJ, Rooney SE, Mather TN, Golde WT.

Infect Immun. 1997 Oct;65(10):4043-7.

47.
48.

Reactivity with a specific epitope of outer surface protein A predicts protection from infection with the Lyme disease spirochete, Borrelia burgdorferi.

Golde WT, Piesman J, Dolan MC, Kramer M, Hauser P, Lobet Y, Capiau C, Desmons P, Voet P, Dearwester D, Frantz JC.

Infect Immun. 1997 Mar;65(3):882-9.

50.

The Lyme disease vaccine candidate outer surface protein A (OspA) in a formulation compatible with human use protects mice against natural tick transmission of B. burgdorferi.

Golde WT, Burkot TR, Piesman J, Dolan MC, Capiau C, Hauser P, Dequesne G, Lobet Y.

Vaccine. 1995 Apr;13(5):435-41.

PMID:
7639011

Supplemental Content

Loading ...
Support Center